======= NCAPD2 =======
== Gene Information ==
* **Official Symbol**: NCAPD2
* **Official Name**: non-SMC condensin I complex subunit D2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9918|9918]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q15021|Q15021]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=NCAPD2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20NCAPD2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/615638|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Regulatory subunit of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases. May target the condensin complex to DNA via its C-terminal domain. {ECO:0000269|PubMed:11136719}.
|Cnd1|
|Cnd1 N|
|condensin core heterodimer|
|nuclear condensin complex|
|meiotic chromosome condensation|
|condensin complex|
|condensed chromosome, centromeric region|
|mitotic chromosome condensation|
|condensed chromosome|
|nuclear chromosome|
|chromosome separation|
|chromosome condensation|
|chromosome organization involved in meiotic cell cycle|
|mitotic sister chromatid segregation|
|histone binding|
|sister chromatid segregation|
|mitotic nuclear division|
|meiotic cell cycle process|
|DNA packaging|
|nuclear chromosome segregation|
|meiotic cell cycle|
|chromosome segregation|
|nuclear division|
|DNA conformation change|
|organelle fission|
|chromatin binding|
|cell division|
|mitotic cell cycle process|
|mitotic cell cycle|
|cell cycle process|
|chromosome organization|
|cell cycle|
|reproductive process|
|reproduction|
|membrane|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.33|
|[[:results:exp210|LB-100 2μM R05 exp210]]|-2.17|
|[[:results:exp513|ONC212 0.15μM R08 exp513]]|-1.97|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-1.91|
|[[:results:exp69|Deguelin 0.05μM R02 exp69]]|-1.85|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|-1.83|
|[[:results:exp333|All-trans-Retinoic-Acid 8μM R07 exp333]]|-1.81|
|[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|-1.76|
|[[:results:exp93|DABN racemic mixture R03 exp93]]|2.21|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 347/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|10/28|
|blood|21/28|
|bone|14/25|
|breast|21/33|
|central nervous system|20/56|
|cervix|2/4|
|colorectal|6/17|
|esophagus|3/13|
|fibroblast|1/1|
|gastric|10/15|
|kidney|10/21|
|liver|9/20|
|lung|36/75|
|lymphocyte|6/14|
|ovary|9/26|
|pancreas|9/24|
|peripheral nervous system|10/16|
|plasma cell|9/15|
|prostate|1/1|
|skin|10/24|
|soft tissue|1/7|
|thyroid|0/2|
|upper aerodigestive|10/22|
|urinary tract|9/29|
|uterus|3/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 708
* **Expression level (log2 read counts)**: 8.76
{{:chemogenomics:nalm6 dist.png?nolink |}}